A share price of Exact Sciences Corp [EXAS] is currently trading at $47.16, up 3.33%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The EXAS shares have gain 3.42% over the last week, with a monthly amount glided 8.54%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Exact Sciences Corp [NASDAQ: EXAS] stock has seen the most recent analyst activity on April 10, 2025, when Mizuho initiated its Outperform rating and assigned the stock a price target of $60. Previously, RBC Capital Mkts started tracking the stock with Sector Perform rating on March 13, 2025, and set its price target to $52. On January 23, 2025, Barclays initiated with a Overweight rating and assigned a price target of $70 on the stock. Wells Fargo started tracking the stock assigning a Overweight rating and suggested a price target of $75 on August 28, 2024. Scotiabank initiated its recommendation with a Sector Outperform and recommended $70 as its price target on June 27, 2024. In a note dated January 02, 2024, The Benchmark Company upgraded an Buy rating on this stock but restated the target price of $91.
Exact Sciences Corp experienced fluctuations in its stock price throughout the past year between $39.97 and $72.83. Currently, Wall Street analysts expect the stock to reach $65.5 within the next 12 months. Exact Sciences Corp [NASDAQ: EXAS] shares were valued at $47.16 at the most recent close of the market. An investor can expect a potential return of 38.89% based on the average EXAS price forecast.
Analyzing the EXAS fundamentals
Trailing Twelve Months sales for Exact Sciences Corp [NASDAQ:EXAS] were 2.76B which represents 10.29% growth. Gross Profit Margin for this corporation currently stands at 0.68% with Operating Profit Margin at -0.37%, Pretax Profit Margin comes in at -0.36%, and Net Profit Margin reading is -0.36%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.36 and Total Capital is -0.2. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 1.05.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 45.69 points at the first support level, and at 44.21 for the second support level. However, for the 1st resistance point, the stock is sitting at 48.11, and for the 2nd resistance point, it is at 49.05.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Exact Sciences Corp [NASDAQ:EXAS] is 2.15. Also, the Quick Ratio is 1.92, while the Cash Ratio stands at 0.69. Considering the valuation of this stock, the price to sales ratio is 3.18, the price to book ratio is 3.64.
Transactions by insiders
Recent insider trading involved Conroy Kevin T, President and CEO, that happened on Nov 13 ’24 when 19500.0 shares were purchased. EVP, GM, Precision Oncology, Baranick Brian completed a deal on Oct 08 ’24 to sell 929.0 shares. Meanwhile, Officer Baranick Brian bought 929.0 shares on Oct 08 ’24.
